MedTrace Logo

Apremilast and Moderate to Severe Chronic Hand Dermatitis

NCT03741933 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-01-11

No results posted yet for this study

Summary

Investigators have designed a pilot study involving chronic hand dermatitis (CHD) patients who attend the dermatology clinic at the George Washington Medical Faculty Associates (GW MFA) in order to assess the efficacy and safety of apremilast treatment for the treatment of moderate to severe CHD.

Conditions

  • Chronic Hand Dermatitis

Interventions

DRUG

Apremilast 30mg

Apremilast 30 mg tablet

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • George Washington University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2019-08-01
Completion
2019-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03741933 on ClinicalTrials.gov